Please assess the completion status of the following clinical trial:

Trial Title: A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* non-ST-elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI) at presentation for index PCI who have successfully completed \>1-year follow-up of RAPID MANAGE or TAILOR-PCI trials without having incurred an ischemic or bleeding outcome while on DAPT~* Patients with DAPT interruption after 1 year will be eligible, if within 3 years of index MI~Patients must also have 1 of the following atherothrombotic risk enrichment criteria:~* age ≥ 65 years~* diabetes~* 2nd prior MI (\> 1 year ago)~* multi-vessel coronary disease~* Creatinine Clearance \< 60mL/min~Exclusion Criteria:~Patients will be excluded from the study if they:~* refuse consent~* are \> 3 years post MI~* are deemed to require a P2Y12 inhibitor~* require oral anticoagulation~* have a history of stroke, transient ischemic attack (TIA) or intracranial bleed~* have had a recent GI bleed or major surgery~* have a life expectancy of \< 1 year~* have a platelet count \< 100,000/μl~* have a bleeding diathesis~* have hematocrit \< 30% or \> 52%~* are on dialysis or have severe liver disease~* are at risk for bradycardia

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Personalized Treatment Algorithm (Type: EXPERIMENTAL): A DAPT score using various patient demographics will be calculated:~If score under 2, patients will receive only aspirin 81 mg once daily~If DAPT score is ≥ 2~* A point-of-care bedside genetic test using a buccal swab will be conducted in order to determine medication regimen~* Those with a positive genetic test (presence of CYP2C19\*2 or CYP2C19\*3), will receive 60mg Ticagrelor twice daily~* Those with a negative genetic test (absence of CYP2C19\*2/\*3) will receive 75mg clopidogrel once daily
- Long-Term Ticagrelor (Type: ACTIVE_COMPARATOR): Patients will be given 60mg Ticagrelor twice daily with no aspirin

Based on this trial design, predict the completion outcome and termination type (if applicable).